Resveratrol, Metabolic Dysregulation, and Alzheimer’s Disease: Considerations for Neurogenerative Disease

Resveratrol, Metabolic Dysregulation, and Alzheimer's Disease: Considerations for Neurogenerative Disease

Resveratrol, metabolic disorders and Alzheimer's disease: consideration of neurodegenerative diseases.

Alzheimer's disease (AD) is often described as a disease in which severe cognitive decline results from Aβ-plaque accumulation, tau tangle formation, and neurodegeneration. It has recently been shown that metabolic dysregulation observed in insulin resistance and type 2 diabetes contributes to the progression of AD. One of the pathologies linking metabolic syndrome to AD is the release of proinflammatory cytokines, which contribute to brain neuroinflammation and mitochondrial dysfunction. This ultimately results in the production and accumulation of amyloid-beta peptides. Improving these metabolic impairments has been shown to be effective in reducing AD progression and improving cognitive function. The polyphenol resveratrol (RSV) improves metabolic disorders. And it benefits the central part of the brain. RSV reduces the release of inflammatory cytokines. Improves the function of mitochondria and improve clearance Aβ-peptide by activating SIRT1 and AMPK RSV is also linked to improved cognitive function.